Skip to main content


Guselkumab shows promise for PsA

Antibodies (illustration)

Findings from the DISCOVER-1 and DISCOVER-2 trials suggest that the interleukin-23 inhibitor guselkumab may be a promising treatment option for people with psoriatic arthritis.

TNF-guided infliximab dose escalation does not improve RA remission rates

IV drip 2

Adjustment of infliximab dosing based on serum tumor necrosis factor-α levels has no impact on rates of remission and sustained treatment discontinuation among patients with rheumatoid arthritis, indicate results from the RRRR trial.

Interleukin inhibitors linked to elevated infection, cancer risk


Results of a meta-analysis suggest that treatment with interleukin inhibitors may be associated with an increased risk for infections and cancer among people with rheumatic diseases.

20-11-2019 | Rheumatology | News | Article

Insufficient diversity in RA clinical trial populations

A systematic review has identified insufficient representation of people from racial minority groups, older individuals, and men in randomized controlled trials investigating treatments for rheumatoid arthritis.

19-11-2019 | Rheumatology | News | Article

Omega-3 supplements may benefit in RA patients

Taking omega-3 is associated with a reduction in measures of rheumatoid arthritis disease activity, suggests real-world data.

18-11-2019 | Rheumatology | News | Article

No benefit of add-on fenebrutinib for patients with SLE

Addition of the Bruton’s tyrosine kinase inhibitor fenebrutinib to standard care does not improve outcomes for patients with systemic lupus erythematosus, suggest findings from a phase II trial.

15-11-2019 | Rheumatology | News | Article

Further investigation of telitacicept may be warranted for SLE

Telitacicept, a recombinant fusion protein targeting B-lymphocyte stimulator and the APRIL proliferation-inducing ligand, has shown potential for the treatment of systemic lupus erythematosus in a phase IIb trial conducted in China.

Twitter Icon Follow medwireNews

Click here
Image Credits